Research
Hormonal
GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.
The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.
ModerateSupportsMEDIUM confidence
By improving glucose removal in white adipose tissue, tirzepatide restored insulin sensitivity even when there was no GLP- 1 receptor -induced weight loss.
Why this rating
Supported by preclinical mouse studies and mechanistic hypotheses.
Source
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
Ioanna A. Anastasiou et al. · Current Obesity Reports · 2025
DOI 10.1007/s13679-025-00623-1
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) produce significantly greater weight loss and glycemic control than selective GLP-1 receptor agonists by synergistically targeting both incretin pathways.Good
- Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →